Investigation Underway: MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Over Securities Law Violations

New York, New York--(Newsfile Corp. - October 3, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of MoonLake Immunotherapeutics ("MoonLake") (NASDAQ: MLTX) concerning possible violations of federal securities laws.

On September 29, 2025, MoonLake announced that its experimental immune disease drug sonelokimab for the treatment of a chronic inflammatory skin condition, hidradenitis suppurativa, failed to meet that one of its late-stage trials. Specifically, the drug failed to "meet its main objective" and the company blamed it on a "higher than expected" placebo response. Analysts were skeptical about approval from regulators as well as the drug's sales potential.

Following this news, MLTX's stock price fell over 89% to open at $6.96 per share.
To obtain additional information, go to:

https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=170759&wire=5&utm_campaign=34

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269083